Edinburgh Research Explorer

Prof Charlie Gourley

Personal Chair of Medical Oncology

Profile photo


Charlie Gourley graduated in Genetics and Medicine from Glasgow University in 1991 and 1994 respectively.

From 1998 to 2005 he trained in Medical Oncology at the Edinburgh Cancer Centre, during which time he obtained a PhD in ovarian cancer genetics (Edinburgh University) and an NHS Education for Scotland Clinician Scientist Award (2004).

He was appointed Senior Lecturer in Medical Oncology at the University of Edinburgh Cancer Research Centre in 2005, Reader in Medical Oncology in 2011 and Professor of Medical Oncology (Personal Chair) in 2012. He received a Scottish Senior Clinical Fellowship Award in 2010.

Professor Gourley’s research focuses on trials of novel targeted agents in gynaecological cancer and the use of translational readouts from these studies in order to facilitate individualisation of care. His team is currently leading a project to perform genomic characterisation of 800 high grade serous ovarian cancer patients from across Scotland in order to determine the clinical consequences of molecular subgroups defined by sequence and copy number and use these findings in order to facilitate the recruitment of patients into trials of molecularly stratified novel therapies.

He is the current chair of the Gynaecological Cancer Intergroup (GCIG) Translational Committee, sits on the Scottish Medicines Consortium and the Scientific Evaluation Committee of the Institut National du Cancer (France).

My research in a nutshell

Ovarian cancer is the sixth most common cause of female cancer death in the UK. Until recently it has been treated as a single disease entity. There is now considerable evidence to demonstrate that ovarian cancers differ in their tissues of origin, their genetic abnormalities, their responsiveness to chemotherapy and the ultimate outcome for patients. 

We are investigating the biology of this disease at the interface between the laboratory and the clinic in order to generate findings that can be directly translated into patient benefit. We do this by characterising the molecular changes that occur in different ovarian cancers and determining how this affects their responsiveness to chemotherapy or novel biological agents.

ID: 250727